CD274 and non-small cell lung carcinoma: Similarly, nivolumab monotherapy wasn’t significantly improved PFS compared with chemotherapy for patients with advanced or recurrent NSCLC whose PD-L1 expression > 5%, and OS benefit was also negative [25].